The regulatory approval of anamorelin for treatment of cachexia in patients with non‐small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.
Abstract Anamorelin is a ghrelin receptor agonist that can be administered orally and thought to improve cancer cachexia by improving appetite and increasing serum insulin‐like growth factor‐1. Anamorelin was not approved for use in Europe. In contrast, the use of anamorelin for cancer cachexia in f...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wiley
2021-02-01
|
| シリーズ: | Journal of Cachexia, Sarcopenia and Muscle |
| オンライン･アクセス: | https://doi.org/10.1002/jcsm.12675 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|